

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023026 A1

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/34 (2017.01)
A61K 31/473 (2006.01)

(21) International Application Number:

PCT/US2022/040425

(22) International Filing Date:

16 August 2022 (16.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/233,659 16 August 2021 (16.08.2021) US

(71) Applicant: **FORESEE PHARMACEUTICALS CO., LTD.** [CN/CN]; 9F-2., No.19-3, Sanchong Road, Nangang Dist., Taipei, 115 (TW).

(72) Inventor; and

(71) Applicant: **LI, Yuhua** [US/US]; 124 Miners Ln, Newark, Delaware 19713 (US).

(72) Inventors: **JANG, Shih-Fan**; No. 259, Datong Rd., Tam-sui Dist., New Taipei City, 251030 (TW). **HUANG, Wen-Yen**; 5F., No. 25, Ln. 128, Fumei St., Xinzhuang Dist., New Taipei City, 242045 (TW). **HUANG, Chia-Ting**; No. 29, Ln. 59, Yixing St., Xizhi District, New Taipei City, 221 (TW).

(74) Agent: **HONG, Enshan**; c/o MagStone Law, 293 Eisenhower Parkway, Suite 135, Livingston, New Jersey 07039 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: POLYMER DEPOT COMPOSITIONS FOR SUSTAINED RELEASE DELIVERY OF VMAT2 INHIBITORS




Fig. 1

(57) Abstract: The present application relates to a sustained release delivery composition of a vesicular monoamine transporter type 2 (VMAT2) inhibitor, a deuterated derivative thereof, a pharmaceutically acceptable salt thereof, an active metabolite thereof, or a prodrug thereof for treatment of hyperkinetic movement disorders including, but not limited to, tardive dyskinesia (TD), Huntington's disease (HD) chorea, tremors, dystonia, chorea, tics, myoclonus, stereotypies, restless legs syndrome, and various other disorders with abnormal involuntary movements. The method of making or using the composition is also disclosed.

[Continued on next page]

Published:

— with international search report (Art. 21(3))